FDA Recall D-0241-2026

Merck Sharp & Dohme LLC · Wilson, NC

Class II Ongoing 153 days on record

Moderate impact — Class II recall — temporary or medically reversible adverse health consequence possible; remote probability of serious adverse health consequence.

Product

Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured by: Novo Nordisk Production Ireland Limited Athlone, Ireland, NDC 0006-3066-03

Lot / code: Lot #: Z014503, Exp 11/15/2027

Quantity: 3 - single dose kits

Reason for recall

Presence of particulate matter: potential presence of metal particulates in the product.

Recall record

Recall number: D-0241-2026
Classification: Class II
Status: Ongoing
Voluntary or mandated: Voluntary: Firm initiated
Firm notification: Letter
Distribution: Nationwide in the USA
Recall initiated: 2025-12-12
Classified by FDA Center: 2025-12-23
FDA published: 2025-12-31
Recalling firm: Merck Sharp & Dohme LLC
Firm location: Wilson, NC

Drug identification

Brand name(s): EMEND
Generic name(s): APREPITANT
Manufacturer(s): Merck Sharp & Dohme LLC
NDC(s): 0006-0461, 0006-0462, 0006-3862, 0006-0464, 0006-3066
Route(s): ORAL

Operational response

Class II recalls indicate possible temporary or reversible health consequences. Remove affected lots from active dispensing. Segregate inventory. Check the firm’s recall notification for guidance on patient outreach.

For the official FDA enforcement record, see FDA's Recall Search.

‹ All recalls